This move is archived. Current quotes and coverage live on the stock page.
Get MSCL alerts:
Satellos Bioscience Inc. faced a notable decline in stock value, closing down 5.24% in the last trading session.
In a challenging trading day, Satellos Bioscience Inc. (MSCL.TO) saw its stock price drop significantly, closing at CA$10.66. This decline comes amid mixed investor sentiment and no recent news to boost confidence.
Investor takeaway: Investors should keep a close eye on Satellos's performance, especially with its recent FDA Fast Track designation, as market reactions can be unpredictable in the biotech sector.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$256.93M
52W high
$18.98
52W low
$7.20
1W change
-5.29%
Beta
1.17
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 35.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+35.1% Upside
Current Price
C$13.08
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
54.8%
Annualized
90-Day Vol
74.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$15.64
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$13.88 | C$11.49 โ C$16.77 |
| 60 trading days | C$14.73 | C$11.28 โ C$19.25 |
| 90 trading days | C$15.64 | C$11.27 โ C$21.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. down 5.24% in one day.
With a market cap of CA$234 million, the recent drop highlights the volatility often seen in biotech stocks, particularly those without consistent news flow.
Bull case
The FDA's Fast Track designation for SAT-3247 could speed up the drug's development, potentially leading to significant future gains if it proves successful.
Bear case
The absence of recent positive developments or news might signal underlying weaknesses that could further impact investor confidence and stock performance.
Advertisement
Market Reaction
Satellos's stock performance reflects broader market sentiments towards biotech firms, especially those waiting for crucial regulatory approvals. The recent drop may indicate investor caution as they await further updates on SAT-3247.
Future Outlook
Despite today's decline, the Fast Track designation from the FDA could pave the way for faster development of SAT-3247. Investors should watch for upcoming clinical trial results and market reactions to any news, as these could significantly affect stock performance. For more details on Satellos's journey, check out their latest updates here.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
